Is oocyte maturity influenced by ovulation trigger type in oocyte donation cycles?

References

• American Society for Reproductive Medicine Practice Committee. (2004). Ovarian hyperstimulation syndrome. Fertility and Sterility, 82, S81–S86. doi: https://doi.org/10.1016/j.fertnstert.2004.05.005.
   PubMedGoogle Scholar
• American Society for Reproductive Medicine Practice Committee. (2013). Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertility and Sterility, 99, 37–43. doi: https://doi.org/10.1016/j.fertnstert.2012.09.028.
   PubMedGoogle Scholar
• Bodri, D., Guillén, J.J., Polo, A., Trullenque, M., Esteve, C., & Coll, O. (2008). Complications related to ovarian stimulation and oocyte retrieval in 4052 oocyte donor cycles. Reproductive Biomedicine Online, 17, 237–243. doi: https://doi.org/10.1016/S1472-6483(10)60200-3.
   PubMed Web of Science ®Google Scholar
• Damewood, M.D., Shen, W., Zacur, H.A., Schlaff, W.D., Rock, J.A., & Wallach, E.E. (1989). Disappearance of exogenously administered human chorionic gonadotropin. Fertility and Sterility, 52, 398–400. doi: https://doi.org/10.1016/S0015-0282(16)60906-8.
   PubMed Web of Science ®Google Scholar
• Delvigne, A., & Rozenberg, S. (2002). Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): A review. Human Reproduction Update, 8, 559–577. doi: https://doi.org/10.1093/humupd/8.6.559.
   PubMed Web of Science ®Google Scholar
• Dyer, C. (2011). Payment to oocyte donors is to be tripled to remedy shortage. BMJ, 343, d6865. doi: https://doi.org/10.1136/bmj.d6865.
   PubMed Web of Science ®Google Scholar
• Galindo, A., Bodri, D., Guillén, J.J., Colodrón, M., Vernaeve, V., & Coll, O. (2009). Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: A randomised clinical trial. Gynecological Endocrinology, 25, 60–66. doi: https://doi.org/10.1080/09513590802404013.
   PubMed Web of Science ®Google Scholar
• Golan, A., & Weissman, A. (2009). Symposium: Update on prediction and management of OHSS. A modern classification of OHSS. Reproductive Biomedicine Online, 19, 28–32. doi: https://doi.org/10.1016/S1472-6483(10)60042-9.
   PubMed Web of Science ®Google Scholar
• Gonen, Y., Balakier, H., Powell, W., & Casper, R.F. (1990). Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. The Journal of Clinical Endocrinology & Metabolism, 71, 918–922. doi: https://doi.org/10.1210/jcem-71-4-918.
   PubMed Web of Science ®Google Scholar
• Griffin, D., Benadiva, C., Kummer, N., Budinetz, T., Nulsen, J., & Engmann, L. (2012). Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders. Fertility and Sterility, 97, 1316–1320. doi: https://doi.org/10.1016/j.fertnstert.2012.03.015.
   PubMed Web of Science ®Google Scholar
• Hernández, E.R., Gómez-Palomares, J.L., & Ricciarelli, E. (2009). No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles. Fertility and Sterility, 91, 1358–1361. doi: https://doi.org/10.1016/j.fertnstert.2008.03.077.
   PubMed Web of Science ®Google Scholar
• Humaidan, P., Kol, S., & Papanikolaou, E.G. (2011). GnRH agonist for triggering of final oocyte maturation: Time for a change of practice? Human Reproduction Update, 17, 510–524. doi: https://doi.org/10.1093/humupd/dmr008.
   PubMed Web of Science ®Google Scholar
• Human Fertilisation and Embryology Authority. (2014). Code of practice. 8th ed. Retrieved from https://www.hfea.gov.uk/media/2062/2017-10-02-code-of-practice-8th-edition-full-version-11th-revision-final-clean.pdf.
   Google Scholar
• Iliodromiti, S., Blockeel, C., Tremellen, K.P., Fleming, R., Tournaye, H., Humaidan, P., & Nelson, S.M. (2013). Consistent high clinical pregnancy rates and low ovarian hyperstimulation pregnancy rates in high-risk patients after GnRH agonist triggering and modified luteal support: A retrospective multicenter study. Human Reproduction, 28, 2529–2536. doi: https://doi.org/10.1093/humrep/det304.
   PubMed Web of Science ®Google Scholar
• Jayaprakasan, K., Herbert, M., Moody, E., Stewart, J.A., & Murdoch, A.P. (2007). Estimating the risks of ovarian hyperstimulation syndrome (OHSS): implications for oocyte donation for research. Human Fertility, 10, 183–187. doi: https://doi.org/10.1080/14647270601021743.
   Google Scholar
• Kasum, M., Danolić, D., Orešković, S., Ježek, D., Beketić-Orešković, L., & Pekez, M. (2014). Thrombosis following ovarian hyperstimulation syndrome. Gynecological Endocrinology, 30, 764–768. doi: https://doi.org/10.3109/09513590.2014.927858.
   PubMed Web of Science ®Google Scholar
• Kolibianakis, E.M., Schultze-Mosgau, A., Schroer, A., van Steirteghem, A., Devroey, P., Diedrich, K., & Griesinger, G. (2005). A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Human Reproduction, 20, 2887–2892. doi: https://doi.org/10.1093/humrep/dei150.
   PubMed Web of Science ®Google Scholar
• Magnusson, Å., Källen, K., Thurin-Kjellberg, A., & Bergh, C. (2018). The number of oocytes retrieved during IVF: A balance between efficacy and safety. Human Reproduction, 33, 58–64. doi: https://doi.org/10.1093/humrep/dex334.
   PubMed Web of Science ®Google Scholar
• Melo, M., Busso, C.E., Bellver, J., Alama, P., Garrido, N., Meseguer, M., … Remohí, J. (2009). GnRH agonist versus recombinant HCG in an oocyte donation programme: A randomized, prospective, controlled, assessor-blind study. Reproductive Biomedicine Online, 19, 486–492. doi: https://doi.org/10.1016/j.rbmo.2009.06.001.
   PubMed Web of Science ®Google Scholar
• O’Neill, K.E., Senapati, S., Maina, I., Gracia, C., & Dokras, A. (2016). GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone. Journal of Assisted Reproduction and Genetics, 33, 1175–1184. doi: https://doi.org/10.1007/s10815-016-0755-8.
   PubMed Web of Science ®Google Scholar
• Office for National Statistics. (2016). Statistical bulletin: Births in England and Wales: Live births, stillbirths, and the intensity of childbearing measured by the total fertility rate. Retrieved from https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/livebirths/bulletins/birthsummarytablesenglandandwales/2016.
   Google Scholar
• Royal College of Obstetricians and Gynaecologists (RCOG). 2016. The Management of Ovarian Hyperstimulation Syndrome Green-top Guideline No. 5 February 2016. Retrieved from https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg5/.
   Google Scholar
• Sauer, M.V. (2001). Defining the incidence of serious complications experienced by oocyte donors: A review of 1000 cases. American Journal of Obstetrics and Gynecology, 184, 277–278. doi: https://doi.org/10.1067/mob.2001.108994.
   PubMed Web of Science ®Google Scholar
• Shapiro, B.S., Daneshmand, S.T., Garner, F.C., Aguirre, M., & Hudson, C. (2011). Comparison of “triggers” using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. Fertility and Sterility, 95, 2715–2717. doi: https://doi.org/10.1016/j.fertnstert.2011.03.109.
   PubMed Web of Science ®Google Scholar
• Sismanoglu, A., Tekin, H.I., Erden, H.F., Ciray, N.H., Ulug, U., & Bahceci, M. (2009). Ovulation triggering with GnRH agonist vs. hCG in the same oocyte donor population undergoing donor oocyte cycles with GnRH antagonist: A prospective randomized cross-over trial. Journal of Assisted Reproduction and Genetics, 26, 251–256. doi: https://doi.org/10.1007/s10815-009-9326-6.
   PubMed Web of Science ®Google Scholar
• Yen, S.S., Llerena, O., Little, B., & Pearson, O.H. (1968). Disappearance rates of endogenous luteinizing hormone and chorionic gonadotropin in man. The Journal of Clinical Endocrinology and Metabolism, 28, 1763–1767. doi:https://doi.org/10.1210/jcem-28-12-1763.
   PubMed Web of Science ®Google Scholar
• Youssef, M.A., Van der Veen, F., Al-Inany, H.G., Mochtar, M.H., Griesinger, G., Nagi Mohesen, M., … van Wely, M. (2014). Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database of Systematic Reviews, 31, CD008046. doi: https://doi.org/10.1002/14651858.CD008046.pub4.
   Google Scholar